BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novo Nordisk A/S (NVO) to Award $80,000 to Local Programs That Help People Living With Diabetes in Seattle as Part of Educational Initiative


8/5/2013 9:55:11 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE, Aug. 1, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that it is now accepting applications from local Seattle nonprofit organizations for 2013 Novo Nordisk Community Care sponsorships. Through the sponsorships, Novo Nordisk will invest $80,000 to support local organizations that educate people living with type 2 diabetes. For more information about the sponsorship criteria and to download an application form, interested nonprofit organizations should visit http://www.novonordisk-us.com/communitycare. Applications are due September 16, 2013.

"More than 670,000 Washingtonians are projected to have diabetes by 2015," said Diana Blankman, Director, US Corporate Giving and Social Impact at Novo Nordisk. "The diabetes epidemic is not slowing down. At Novo Nordisk, we consider it our duty to continue to work closely with these community-based organizations that are vital to creating change in diabetes education from the ground up."

Since the program's inception in 2011, Novo Nordisk Community Care has awarded nearly $715,000 to organizations in nine markets across the country and has sponsored more than 36 diverse community-based programs. Last year's sponsored programs were selected for their distinctive applications focused on education and resources for patients, ranging from healthy living educational workshops and dance classes, community health advocate/peer mentor training and patient empowerment programs. This year, Novo Nordisk will offer new sponsorship opportunities to eligible nonprofit organizations dedicated to educating and empowering patients in Seattle to become more engaged in their health and management of type 2 diabetes.

Diabetes has become a global health crisis and is taking a major toll on our communities, including Seattle. A recent model from the Institute for Alternative Futures, commissioned by Novo Nordisk, estimates that the number of Americans living with diabetes will increase 64 percent between 2010 and 2025, affecting more than 53 million people. And, in Washington, it's estimated that the number of people with diabetes will increase 88 percent between 2010 and 2025, to affect more than 975,000 people, including more than 500,000 people in Seattle. This dramatic increase could mean a total of $9.6 billion in total medical and indirect societal costs of diabetes for the state of Washington by 2025.

About Novo Nordisk

Novo Nordisk is a global health care company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,700 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

SOURCE Novo Nordisk

Hey, check out all the research scientist jobs. Post your resume today!


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES